PharmaBoardroom

Interview: Augusto Mitidieri – CEO, Sintetica, Switzerland

Sintetica, Switzlerland’s longtime leader in local anesthesia and pain relief with development efforts in neuromodulation, started an ambitious…

Interview: Laurent Jossart – Executive Vice-President,…

Laurent Jossart of Luxair Cargo reveals his firm’s resolute philosophy and determination to provide operational excellence and using Luxembourg’s…

Interview: Massimiliano Colella – Senior Vice President…

Recently appointed Senior Vice President of Asia Pacific, Massimiliano Colella speaks about Smith & Nephew's reasons for establishing a presence…

Interview: Iwer Baecker – Managing Director, Bayer Ireland

Iwer Baecker, MD of Bayer Ireland, outlines the Irish affiliate’s impressive growth in the past few years, the strategy of New Bayer and how it…

Mexico Facts and Figures Snapshot

This chart gives an insight into the phenomenal importance of the pharmaceutical industry to Mexico, in terms of both monetary value and employment…

Navigating Healthcare Budget Cuts in Mexico

"80 percent of our health expenditures are used to treat only 20 percent of the Mexican population"

Interview: Kuntal Baveja – Country Head & President,…

Kuntal Baveja, country head and president of Sandoz Philippines Corporation discusses the company’s expanding portfolio in the country and how the…

Interview: Nic Alexakis – CEO, Swiss Biotech Association

The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also…

Interview: Sugantha Natarajan – Director, Healthcare, Asia…

DB Schenker’s director of healthcare in Asia Pacific, Sugantha Natarajan describes the company’s presence across the region, while emphasizing the…

Interview: Francisco Rodriguez – General Manager Mexico…

Francisco Rodriguez, general manager Mexico and Latin America at Mundipharma, provides an overview of the customized market approach that has allowed…

Why the J&J Takeover of Actelion Looks Unlikely

Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a…

Rudolf Hanko – CEO, Siegfried, Switzerland

Developing manufacturing capacity for as yet unapproved drugs can create huge risk on innovators’ balance sheets, risk which can be mitigated by…

Tagged with